Clinical trial
Kanglaite Injection Phase I Study
NCT00031031 · KangLaiTe USA, Industry · Completed
Key facts
| NCT number | NCT00031031 |
|---|---|
| Title | Kanglaite Injection Phase I Study |
| Official title | Phase I Study of KLT in Patients With Solid Tumors Refractory to Standard Therapy |
| Lead sponsor | KangLaiTe USA, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors Refractory To Standard Therapy, Neoplasms |
| Intervention type | Drug |
| Interventions | Kanglaite Injection (KLT) |
| Enrollment | 16 |
| Start date | Jun 1, 2001 |
| Completion | Nov 1, 2002 |
| First posted | Feb 22, 2002 |
| Last update posted | Nov 27, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: